[en] This review focuses on new antibiotics, particularly for gram-positive infections, new antiretroviral drugs, new treatment of fungal infections and indications of miltefosine in the treatment of leishmaniasis.
Disciplines :
Immunology & infectious disease
Author, co-author :
GIOT, Jean-Baptiste ; Centre Hospitalier Universitaire de Liège - CHU > Maladies infectieuses et médecine interne générale
Mukeba Tshialala, D.
Mayasi Ngongo, N.
Frippiat, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Maladies infectieuses et médecine interne générale
Leonard, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Maladies infectieuses et médecine interne générale
Moutschen, Michel ; Université de Liège - ULiège > Département des sciences cliniques > Immunopathologie - Transplantation
Language :
French
Title :
Avancees therapeutiques en pathologie infectieuse au cours de la derniere decennie
Alternative titles :
[en] New Treatments of Infectious Diseases over the Last Ten Years
Publication date :
2007
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Ackerman G, Rodloff A. - Drugs of the 21st century: telithromycin (HMR 3647) - the first ketolide. J Antimicrob Chemother, 2003, 51, 497-511.
Jacobs MR. - Optimalisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microb Infect, 2001, 7, 589-596.
Clay KD, Hanson JS, Pope SD, et al. - Brief communication : severe hepatotoxicity of telithromycin : three case reports and literature review. Ann Intern Med, 2006, 144, 415-420.
Marchese A, Schito GA. - Recent findings from multinational resistance surveys: are we 'PROTEKTed' from resistance? Int J Antimicrob Agents, 2007, 29, S2-5.
Andriole VT. - The quinolones: past, present, and future. Clin Infect Dis, 2005, 41, 113-119.
Niederman MS. - Challenges in the management of community-acquired pneumonia: the role of quinolones and moxifloxacin. Clin Infect Dis, 2005, 41, 158-166.
Wispelwey B. - Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Infect Dis, 2005, 41, 127-135.
Lode H, Allewelt M. - Role of the newer fluoroquinolones in lower respiratory tract infections. J Antimicrob Chemother, 2002, 49, 709-712.
Fortun J, Martin-Davila P, Navas E, et al. - Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother, 2005, 56, 180-185.
Birmingham MC, Rayner CR, Meagher AK, et al. - Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis, 2003, 36, 159-168.
Jaksic B, Martinelli G, Perez-Oteyza J, et al. - Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis, 2006, 42, 597-607.
Shorr AF, Kunkel MJ, Kollef M. - Linezolid versus vancomycine for Staphylococcus aureus bacteraemia: polled analysis of randomized studies. J Antimicrob Chemother, 2005, 56, 923-929.
Wunderink RG, Rello J, Cammarata SK, et al. - Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest, 2003, 124, 1789-1797.
Weigelt J, Itani K, Stevens D, et al. - Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother, 2005, 49, 2260-2266.
Drees M, Boucher H. - New agents for Staphylococcus aureus endocarditis. Curr Opin Infect Dis, 2006, 19, 544-550.
Rubinstein E, Isturiz R, Standiford HC, et al. - World-wilde assessment of linezolid's clinical safety and tolerability : comparator-controlled phase III studies. Antimicrob Agents Chemother, 2003, 47, 1824-1831.
Hancock RE. - Mechanisms of action of newer antibiotics for gram-positive pathogens. Lancet Infect Dis, 2005, 5, 209-218.
Bouchillon SK, Hoban DJ, Johnson BM, et al. - In vitro activity of tigecycline against 3989 gram-negative and gram-positive clinical isolates from the United States tigecycline evaluation and surveillance trial (TEST program 2004). Diagn Microbiol Infect Dis, 2005, 52, 173-179.
Stryjewski ME, Chu VH, O'Riordan WD, et al. - Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria : FAST 2 Study. Antimicrob Agents Chemother, 2006, 50, 862-867.
Fulco P, Wenzel RP. - Ramoplanin : a topical lipoglycodepsipeptide antibacterial agent. Expert Rev Anti Infect Ther, 2006, 4, 939-945.
Treatment for adult HIV infection. 2006 recommendations of the international AIDS Society-USA Panel. JAMA, 2006, 296, 827-843.
European Guidelines for the clinical management and treatment of HIV infected adults 2005. http://www.eacs.eu.download/Euroguidelines4151105.pdf.
Tomas C. - Nucleotide HIV reverse transcriptase inhibitors : tenofovir and beyond. Curr Opin HIV AIDS, 2006, 1, 373-379.
Wilkin A, Feindberg J. - New targets in antiretroviral therapy 2006. Curr Opin HIV AIDS, 2006, 1, 437-441.
Flilckiger U, Marchetti O, Bille J, et al. - Treatment options of invasive fungal infections in adults. Swiss Med Wkly, 2006, 136, 447-463.
Sundar SS, Jha TK, Thakur CP, et al. - Oral miltefosine for indian visceral leishmaniasis. N Engl J Med, 2002, 347, 1739-1746.
Soto J, Toledo J, Valda L, et al. - Treatment of bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis, 2007, 44, 350-356.
Ritmeijer K, Dejenie A, Assefa Y, et al. - A comparison of ioltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis, 2006, 43, 357-364.
